Compare Medpace Holdings Inc (MEDP) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Plby Group Inc — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Plby Group Inc trades at $0.98 (market cap $118.21M). The key difference: Medpace Holdings Inc is far larger — about 142.3× Plby Group Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Plby Group Inc for 24 Days on average.
| MEDP | PLBY | |
|---|---|---|
Market Cap | $16.82B | $118.21M |
Volume | 223,093 | 919,783 |
Sector | Health | Consumer Cyclical |
52-Week High | $630.19 | $2.71 |
52-Week Low | $393.42 | $0.99 |
Typical Hold Time | 14 Days | 24 Days |
Enterprise Value | $16.44B | $263.80M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
PLBY trades at $0.9867, down 3.26% today, amid bearish technical signals but with improving fundamentals. Recent earnings show a Q2 2026 beat, and cash flow turned positive in 2025. The company is expanding leadership to drive growth, yet faces high debt and negative equity. Analyst consensus is 75% buy, reflecting optimism on turnaround efforts.
Outlook hinges on execution of growth initiatives and debt management. Opportunities include brand licensing expansion and media strategy, but risks from high leverage and competitive pressures persist. Investors should weigh improving operational trends against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
